←Back to Expert Scholars
Translational Medicine / 转化医学DNA Methylation, AML Therapy
Michael Lubbert
MD
🏢University Medical Center Freiburg🌐Germany
Professor of Internal Medicine
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Michael Lubbert has led European randomized trials of decitabine in older patients with AML, including the DACO-016 study. His work established hypomethylating agents as standard therapy for unfit elderly leukemia patients. He directs hematology at Freiburg.
Share:
🧪Research Fields 研究领域
decitabine
AML
elderly leukemia
hypomethylating agents
clinical trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Michael Lubbert 的研究动态
Follow Michael Lubbert's research updates
留下邮箱，当我们发布与 Michael Lubbert（University Medical Center Freiburg）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment